1. Home
  2. TRAX vs EFSC Comparison

TRAX vs EFSC Comparison

Compare TRAX & EFSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRAX

First Tracks Biotherapeutics Inc. Ordinary Shares

N/A

Current Price

$47.69

Market Cap

1.9B

Sector

Health Care

ML Signal

N/A

Logo Enterprise Financial Services Corporation

EFSC

Enterprise Financial Services Corporation

N/A

Current Price

$62.26

Market Cap

2.1B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
TRAX
EFSC
Founded
2025
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.1B
IPO Year
2026
1996

Fundamental Metrics

Financial Performance
Metric
TRAX
EFSC
Price
$47.69
$62.26
Analyst Decision
Strong Buy
Buy
Analyst Count
12
7
Target Price
★ $75.17
$69.57
AVG Volume (30 Days)
★ 716.3K
199.6K
Earning Date
11-03-2026
10-21-2026
Dividend Yield
N/A
★ 2.31%
EPS Growth
N/A
★ 9.94
EPS
N/A
★ 3.54
Revenue
N/A
N/A
Revenue This Year
N/A
$3.10
Revenue Next Year
N/A
$6.95
P/E Ratio
★ N/A
$17.62
Revenue Growth
N/A
N/A
52 Week Low
$15.69
$51.79
52 Week High
$54.78
$68.73

Technical Indicators

Market Signals
Indicator
TRAX
EFSC
Relative Strength Index (RSI) 58.17 53.12
Support Level $35.11 $61.66
Resistance Level $48.94 $65.19
Average True Range (ATR) 3.20 1.17
MACD 0.15 -0.00
Stochastic Oscillator 39.33 22.51

Price Performance

Historical Comparison
TRAX
EFSC

About TRAX First Tracks Biotherapeutics Inc. Ordinary Shares

First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.

About EFSC Enterprise Financial Services Corporation

Enterprise Financial Services Corporation is a financial holding company. It offers banking and wealth management services to individuals and business customers located in Arizona, California, Florida, Kansas, Missouri, Nevada, and New Mexico, in addition to loan and deposit production offices throughout the United States. The company offers a broad range of business and personal banking services including wealth management services. Its Lending services include commercial and industrial, commercial real estate, real estate construction and development, residential real estate and consumer loans.

Share on Social Networks: